12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tirasemtiv: Phase IIb amended

Cytokinetics amended the protocol of the international Phase IIb BENEFIT-ALS trial to increase enrollment to 680 patients from 500 and to update the statistical methods. The amendments are designed to maintain the originally intended statistical power of the trial following a programming error that accidentally switched 58 patients initially treated with tirasemtiv to placebo. The study's...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >